http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2557547-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_add32758faf89cdeabf043a846d5e8a4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N43-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N43-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate | 2010-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_867f36746ff9183ca37c09946d3f7ea3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_999495bccb22dda32b853888e99e2833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_474f46a645e02dbd186db3ed33930ba1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6d9f07cded4910e624223dfe7061ac8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_875b145e4f4b1d1221dd208c822b1d57 |
| publicationDate | 2015-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2557547-C2 |
| titleOfInvention | Crystalline forms of 6-(1h-imidazol-1-yl)-2-phenylquinazoline and its salts |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to novel crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline of formula (I) in form of salt, selected from hydrochloride, (L)-tartrate and maleate. Compounds possess strong analgising action and can be applied in therapy in treatment of pain in case of such diseases as rheumatoid arthritis, osteoarthritis, pathologies of inflammatory diseases, gastrointestinal tract diseases, etc. Each crystalline form of salt is characterised by spectrum of X-ray powder diffraction (XRPD). Crystalline form of hydrochloride is also characterised by melting point with decomposition at approximately 240°C. Crystalline form of (L)-tartrate and crystalline form of maleate are also characterised by DSC thermograms and FTIR spectra. Crystalline form of maleate is additionally characterised by triclinic system with parameters of crystalline cell a = 8.9412 (5) E, b = 9.8081 (5) E, c = 10.5922 (6) E, α: 90.517° (4), β = 101.969° (5), γ = 99.132° (4), V = 896.34 (8) E 3 , space group P-1. n EFFECT: salts possess improved solubility, bioavailability and stability. n 3 cl, 66 dwg, 19 tbl, 65 ex |
| priorityDate | 2009-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.